

Translating ADC Innovation into Next-Gen Value Creation

Annual Shareholders' Meeting

June 26, 2026

© 2026 OBI Pharma Inc. All Rights Reserved.

The logo for OBI PHARMA, featuring the letters 'OBI' in a bold, teal font with a white circle around the 'O', and the word 'PHARMA' in a smaller, teal font below it.

OBI
PHARMA

Safe Harbor Statement

This presentation contains certain forward-looking statements.

These forward-looking statements may be identified by words such as “believes,” “expects,” “anticipates,” “projects,” “intends,” “should,” “seeks,” “estimates,” “future,” “or similar expressions or by discussion of, among other things, strategy, goals, plans, or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1. Pricing and product initiatives of competitors
2. Legislative and regulatory developments and economic conditions
3. Delay or inability in obtaining regulatory approvals or bringing products to market
4. Fluctuations in currency exchange rates and general financial market conditions
5. Uncertainties in the discovery, development, or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products
6. Increased government pricing pressures
7. Interruptions in production
8. Loss of or inability to obtain adequate protection for intellectual property rights
9. Litigation
10. Loss of key executives or other employees
11. Adverse publicity and news coverage

OBI Pharma cautions that this foregoing list of factors is not exhaustive. There may also be other risks that management is unable to predict at this time that may cause actual results to differ materially from those in forward-looking statements. **You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. OBI undertakes no obligation to update publicly or revise any forward-looking statements.**

Any statements regarding earnings growth is not a profit forecast and should not be interpreted to mean that OBI’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed published earnings or earnings per share forecasts of OBI Pharma, Inc.

Agenda

Ya-Chi Chen, PharmD
Acting CEO and CSO



- **OBI's Positioning and Goals**
- **Core technology and innovative pipeline**
- **OBI's value and future roadmap**

OBI Pharma

Advancing from ADC Platform Innovation to Global Licensing

Focuses on Next-Generation Antibody-Drug Conjugates (ADCs) in **Precision Oncology**



Proprietary Platform

OBRION® Engine
Next-gen conjugation
technology



Differentiated Assets

First / Best-in-Class
ADC assets



Licensing Value

Global business
development upside

Integrated Leadership to Drive Value Creation

Executive Team



Ya-Chi Chen, PharmD
Acting CEO & CSO



Dong Xu, PhD
Chief Medical Officer



Colin Kao, CPA
Chief Operating Officer



Jukka Muhonen
Executive Director,
BD (USA)



Board of Directors




Kung-Yee Liang, PhD
Chairman



Yeong-Fang Chiang, PhD
Vice Chairman


Next-Gen ADC Innovation Surges as Global Pharma Deepens Strategic Commitment

Compound Annual Growth Rate (CAGR) Reaches 87.5%



Obrion®: Core Technologies and Competitive Advantages

Four Core Technologies Enabling Next-Generation ADC Innovation
Addressing Conventional ADC Challenges in Homogeneity, Stability, and Payload Design



Initiated clinical validation (US and Taiwan)

Lower non-specific toxicity

GMP manufacturing with high yield

Overcome DAR Constraints
Enable DAR 24 and DAR 16 for dual and single payload ADCs, respectively.

GlycOBI®

Site-specific glycan conjugation platform
Maintain antibody integrity and manufacturing flexibility

GlycOBI DUO®

Next-gen dual payload glycan conjugation platform
Precise and tunable drug to antibody ratio

HYPrOBI®

Hydrophilic and stable linker design

EndoSymeOBI®

Patented dual function enzyme

Enzyme Manufacturing



Next-Generation ADC Technology Platform

Obrion Engine™
OBI Enzyme technology

✓ Proven Manufacturing Capabilities

ThiOBI® GlycOBI®

✓ ADC Enabling Technologies

EndoSymeOBI® GlycOBI DUO™
HYPrOBI™

✓ Out-licensing Opportunities

✓ Specialized Personnel

Enzyme Production

- Total Capacity: 60L
- 600ml – 10,000mL
- 2 X 5 L,
- 1 X 50 L (Target 2027)
- ISO 17025 (Target 2026)



Contact Us: ✉ service@obipharma.com ☎ +886-2-2655-8799

Integrated Enzyme Facility

Ensures consistency, scalability, and rapid support for ADC development

Downstream process room




Reagent preparation room



Upstream process room




Washing room



Diversified Pipeline Driven by Platform Innovation

Strategize Portfolio Growth

- In-license
- Research Collaboration



OBI-902: Ongoing Phase 1 Study

United States





- Scripps Green Hospital
- MD Anderson Cancer Center
- NEXT Oncology

Taiwan



- Shuang Ho Hospital
- China Medical University Hospital
- Taipei Municipal Wanfang Hospital

Cancer Types Enrolled



OBI-201: Overcome “GATE” with dual TROP2 x HER2 design

Boost targeted delivery

Enhance cancer specificity

Novel approach for the
HER2 low/resistant cancer

Enhertu[®] successor



 **ENHERTU[®]**
trastuzumab deruxtecan

~\$5B USD in 2025



CAGR 17.6%



HER2-positive
(IHC 3+) 8.7%



OBI-221 Enabled by Glyc **OBI DUO**[®]

First-in-Class bispecific (cMet x HER3) dual-payload ADC with high potential in GI and NSCLC

Biology-Driven
Dual-Target Strategy
to Overcome Resistance




USD 6.7 B USD 14.25 B



2026 Oncology Market

Maximize Tumor Kill
Through Dual-Phase Attack



OBI Pharma's Value Creation Pathway




ADC Asset

- Commercial licensing
- Milestone payment or commercial royalty



Platform

- Conjugation technology licensing for linker, payload, and others



Proprietary Enzyme

- Leverage manufacturing capacity to generate revenue and strengthen cash flow



Strategic Collaboration

- Co-development to advance products and expend clinical study with risk sharing strategy

OBI identified as a key player in ADC industry

The only dual payload platform developer

May 2026

NEWS CATEGORY	DISCOVERY/ PRECLINICAL	PHASE 1	PHASE 2	PHASE 3/ APPROVED	ADCs			
					Company	Asset	Target	Payload
REGULATORY					GSK	Blenrep	BCMA	TUBi
CLINICAL					Pfizer/astellas	PADCEV	Nectin-4	TUBi
CORPORATE					石药集团	BL-B01D1	EGFR/HER3	Topo1i
DEALS					石药集团	SYS6051		
					华东医药	HS-20093		
					KELUN-BIOTECH	SKB315		
					诗健生物	ESG406		
					IPSEN	IPN60300		
					Gan & Lee	GLR1059		
					AstraZeneca	Datroway		
					Daiichi-Sankyo	PF-08046037		
					adcendo	CKD-703	C-MET	TUBi
					Lilly	ADCE-T02	TF	Topo1i
					Mabwall	Safetabart	Fra	Topo1i
					CELLTRION	Mipitecan		
						9MW2821	Nectin-4	Topo1i
						CT-P70/71/73	C-MET/Nectin-4	Topo1i
						BL-M07D1	HER2	Topo1i
					PLATFORM			
					OBI PHARMA	HY Protecan/Obrion Engine		

About Phenomiqs:
A strategic consultancy dedicated to providing the most impactful insights and strategic guidance.



Sustainable Development Goals and Roadmap



Short-term

- Accelerate global commercial out-licensing of platform technologies and core assets
- Advance next-generation ADC development and novel payload innovation
- Expand and strengthen a diversified product pipeline
- Maintain strong cash discipline



Mid-term

- Continuously upgrade proprietary platform technologies
- Continue advancing global clinical development and regulatory progress (including BLA submission)



Long-term

- Evolve into a globally competitive, innovation-driven biopharmaceutical company with the capability to develop blockbuster drugs

Thank you

